<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046900</url>
  </required_header>
  <id_info>
    <org_study_id>2019P001543</org_study_id>
    <nct_id>NCT04046900</nct_id>
  </id_info>
  <brief_title>Vaginal Microbiota Transplant</brief_title>
  <acronym>MOTIF</acronym>
  <official_title>Vaginal Microbiota Transplant to Promote Lactobacillus-dominant Cervicovaginal Communities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Douglas Kwon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore a&#xD;
      Lactobacillus dominant vaginal microbial community in women with recurrent bacterial&#xD;
      vaginosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a randomized, double-blind, placebo-controlled trial to evaluate&#xD;
      the safety of vaginal microbiota transplant (VMT) in women with recurrent bacterial vaginosis&#xD;
      (BV), and to assess the ability of antibiotic treatment plus vaginal microbiota transplant to&#xD;
      establish a Lactobacillus-dominant vaginal community as compared to antibiotic treatment&#xD;
      alone. The underlying hypothesis is that the VMT will lead to less inflammation and higher&#xD;
      prevalence of vaginal Lactobacillus compared to antibiotics alone. The transplant material&#xD;
      will be vaginal fluid collected from healthy donors using a disposable menstrual cup. Donors&#xD;
      undergo extensive testing for possible infections to ensure the safety of the donated&#xD;
      material.&#xD;
&#xD;
      Study Visits and Procedures: In addition to the pre-screening eligibility phone call and&#xD;
      screening visit, there will be two treatment study visits and six post-VMT follow up visits&#xD;
      at weeks 3, 5, 7, 11, 15, and 27. The baseline visit will occur within 45 days of the&#xD;
      screening visit.&#xD;
&#xD;
      Phone Screen: A brief phone discussion to explain approach and alternatives (see details&#xD;
      below in &quot;Technical Methods&quot;). A set of short screening questions will be asked to identify&#xD;
      women with clear exclusion criteria for participation.&#xD;
&#xD;
      Visit 1, Screening Visit: At the screening visit, after written informed consent is obtained,&#xD;
      the information from the pre-screening questionnaire will be reviewed with the subject and&#xD;
      updated as necessary. Blood and vaginal specimens will be collected. The VMT process will be&#xD;
      explained in detail and subjects will have the opportunity to inspect an example applicator&#xD;
      if interested. Subjects will be counseled not to have vaginal intercourse or insert anything&#xD;
      into their vagina from the 72 hours prior to the first transplant dose until 72 hours after&#xD;
      the second transplant dose.&#xD;
&#xD;
        -  Review eligibility and understand/see applicator&#xD;
&#xD;
        -  Obtain informed consent&#xD;
&#xD;
        -  Height, weight measurements&#xD;
&#xD;
        -  Subjects will be given information about how to perform vaginal swab collections (see&#xD;
           vaginal swab collection document)&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Pelvic exam&#xD;
&#xD;
        -  Screening labs: Complete blood cell count w/ differential, comprehensive metabolic&#xD;
           panel, Pap/HPV (human papillomavirus) testing, gonorrhea, chlamydia, trichomonas&#xD;
           testing. HIV, Hepatitis B&amp;C, Herpes.&#xD;
&#xD;
        -  Urine pregnancy test&#xD;
&#xD;
        -  Behavior and sexual assessment&#xD;
&#xD;
      Visit 2: Baseline, Week 1 (occurs immediately prior to menses)&#xD;
&#xD;
        -  Self-Administered Vaginal Swab and soft cup collection&#xD;
&#xD;
        -  Blood draw&#xD;
&#xD;
        -  Pelvic Exam: cervical swabs, cytobrush&#xD;
&#xD;
        -  Symptom and Sexual Behavior Assessment&#xD;
&#xD;
        -  Assignment into study groups using block randomization&#xD;
&#xD;
        -  Subjects will be given 7-day course of: Metronidazole 500mg PO every 12 hours&#xD;
&#xD;
      Visit 3: First Transplant Administration, Week 2&#xD;
&#xD;
        -  Self-collected Vaginal Swab and soft cup collection&#xD;
&#xD;
        -  Pelvic Exam: VMT/placebo Administration&#xD;
&#xD;
        -  Symptom and Sexual Behavior Assessment&#xD;
&#xD;
      Visit 4: Second Transplant Administration, Week 2&#xD;
&#xD;
        -  Self-Administered Vaginal Swab&#xD;
&#xD;
        -  Pelvic Exam: VMT/Placebo Administration&#xD;
&#xD;
        -  Symptom and Sexual Behavior Assessment&#xD;
&#xD;
      Visits 5-10: Post-transplant follow ups, Weeks 3, 5, 7, 11, 15, 27&#xD;
&#xD;
        -  Blood draw (visit 7 only)&#xD;
&#xD;
        -  Self-Administered Vaginal Swab&#xD;
&#xD;
        -  Self-Administered soft cup collection (visit 5, 7 &amp; 9)&#xD;
&#xD;
        -  Symptom and Sexual Behavior Assessment&#xD;
&#xD;
        -  Pelvic Exam: cervical swabs, cytobrush (visits 7 &amp; 9)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Lactobacillus-dominant microbiome</measure>
    <time_frame>5 weeks after intervention</time_frame>
    <description>Lactobacillus dominant = relative abundance of Lactobacillus in the vaginal microbial community &gt; 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Lactobacillus-dominant microbiome</measure>
    <time_frame>1, 3, 7 weeks, 4 and 6 months after intervention</time_frame>
    <description>Characterization of the vaginal microbial community using 16S rRNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women reporting adverse events</measure>
    <time_frame>1, 3, 5, 7 weeks, 4 and 6 months after intervention</time_frame>
    <description>Report of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Recurrent Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Vaginal microbiome transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women in this group will be randomized to receive two doses of sterile saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaginal microbiome transplant</intervention_name>
    <description>Vaginal fluid from healthy donors</description>
    <arm_group_label>Vaginal microbiome transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Metronidazole</intervention_name>
    <description>500mg oral metronidazole twice daily for 7 days</description>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_label>Vaginal microbiome transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile saline</intervention_name>
    <description>700 uL of sterile saline placed in the vagina as a placebo intervention.</description>
    <arm_group_label>Saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Premenopausal women, 18- 50 years old&#xD;
&#xD;
          -  Abnormal Nugent score: &gt; 3&#xD;
&#xD;
          -  History of recurrent bacterial vaginosis (BV) (3 or more documented episodes in past&#xD;
             12 months)&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, study participants&#xD;
             must agree to use an effective contraceptive while actively participating in the&#xD;
             protocol. At least one of the following methods MUST be used:&#xD;
&#xD;
               -  Condoms (male or female), with or without a spermicidal agent&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Hormonal contraceptive (including oral pills, vaginal ring, implant, injection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant vaginal, cervical, or uterine disease including but&#xD;
             not limited to: cancer of the female reproductive tract, prior hysterectomy, high&#xD;
             grade cervical dysplasia (CIN III), or diagnosed with cervicovaginal infection (with&#xD;
             the exception of bacterial vaginosis) within the 30 days prior to the procedure.&#xD;
&#xD;
               -  Allergy to metronidazole&#xD;
&#xD;
               -  Use of investigational therapies or investigational vaccines within 90 days prior&#xD;
                  to study entry&#xD;
&#xD;
               -  Use of any immunomodulatory agents within 30 days prior to study enrollment.&#xD;
                  Subject taking any of the following medications: systemic steroids (inhaled or&#xD;
                  nasal steroid therapy is permitted), interleukins, systemic interferons (e.g.&#xD;
                  local injection of interferon alpha for treatment of HPV is permitted) or&#xD;
                  systemic chemotherapy.&#xD;
&#xD;
               -  History of coronary artery disease, myocardial infarction, COPD, chronic renal&#xD;
                  failure, decompensated cirrhosis, or any other condition that in the opinion of&#xD;
                  the investigator will compromise ability to participate in the study.&#xD;
&#xD;
               -  History of abnormal pap smear within 12 months&#xD;
&#xD;
               -  Insertion of levonorgestrel-containing IUD within 3 months prior to study entry&#xD;
&#xD;
               -  Either breastfeeding or pregnant within 24 weeks prior to study entry&#xD;
&#xD;
               -  Use of probiotics and prebiotics (supplements and products, oral or vaginal)&#xD;
                  within 30 days of the study. (NOTE: Oral yogurt with live cultures is allowed.)&#xD;
&#xD;
               -  Routine use of oral antibiotics i.e. daily use for acne, Hidradenitis&#xD;
                  suppurativa, or regular use for post-coital urinary tract infection prophylaxis&#xD;
                  within the past 30 days.&#xD;
&#xD;
               -  Taken non-metronidazole antibiotics in last 30 days&#xD;
&#xD;
               -  BMI &gt; 40&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doug Kwon, MD, PhD</last_name>
    <phone>857-268-7009</phone>
    <email>dkwon@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline Mitchell, MD, MPH</last_name>
      <phone>617-724-2182</phone>
      <email>caroline.mitchell@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Caroline Mitchell, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Douglas Kwon</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

